Tracking and tackling the tumor dynamics clonal evolution: osimertinib rechallenge after interval therapy might be an effective treatment approach in ()-mutant non-small cell lung cancer (NSCLC).

J Thorac Dis

Department of Oncology, University Hospital of Geneva, Geneva, Switzerland.

Published: April 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096286	PMC
http://dx.doi.org/10.21037/jtd-22-98	DOI Listing

Publication Analysis

tracking tackling

tackling tumor

tumor dynamics

dynamics clonal

clonal evolution

evolution osimertinib

osimertinib rechallenge

rechallenge interval

interval therapy

therapy effective

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!